Purpose: This article reviews the cardiovascular benefits and reduction in Major Adverse Cardiovascular Events (MACE) and secondary cardiovascular risk reduction associated with the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA). This article focuses on the treatment of type 2 diabetes mellitus, both with and without known cardiovascular disease. Method: A literature review of the studies acquired through the PubMed database on SGLT-2i: canagliflozin, dapagliflozin, and empagliflozin; as well as GLP1-RA: exenatide, dulaglutide, and semaglutide was conducted. Cardiovascular Outcome Trials (CVOT) for each of the six drugs were accepted for evaluation in this literature revie...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
INTRODUCTION: Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 recepto...
Objective: There is substantial interest in how GLP-1RA (glucagon-like peptide-1 receptor agonists) ...
Objective: There is substantial interest in how GLP-1RA (glucagon-like peptide-1 receptor agonists)...
BACKGROUND:Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose contransporter-2 i...
BACKGROUND: Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SG...
Treatment intended to lower cardiovascular (CV) risk in patients with diabetes has always been a pri...
To identify potential application of GLP1-RAs (glucagon-like peptide-1 receptor agonists) and SGLT2-...
Background: The differential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and gluc...
Background: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the...
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outc...
Background: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
OBJECTIVE: To assess associations between current use of sodium-glucose cotransporter 2 inhibitors (...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
INTRODUCTION: Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 recepto...
Objective: There is substantial interest in how GLP-1RA (glucagon-like peptide-1 receptor agonists) ...
Objective: There is substantial interest in how GLP-1RA (glucagon-like peptide-1 receptor agonists)...
BACKGROUND:Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose contransporter-2 i...
BACKGROUND: Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SG...
Treatment intended to lower cardiovascular (CV) risk in patients with diabetes has always been a pri...
To identify potential application of GLP1-RAs (glucagon-like peptide-1 receptor agonists) and SGLT2-...
Background: The differential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and gluc...
Background: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the...
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outc...
Background: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
OBJECTIVE: To assess associations between current use of sodium-glucose cotransporter 2 inhibitors (...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
Ideal drugs to improve outcomes in type 2 diabetes mellitus (T2DM) are those with antiglycemic effic...
INTRODUCTION: Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 recepto...